Join Growin Stock Community!

Arrivent biopharma, inc. common stockAVBP.US Overview

US StockHealthcare
(No presentation for AVBP)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

AVBP AI Insights

AVBP Overall Performance

AVBP AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

AVBP Recent Performance

-2.23%

Arrivent biopharma, inc. common stock

0.05%

Avg of Sector

-0.31%

S&P500

AVBP PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

AVBP Key Information

AVBP Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

AVBP Profile

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Price of AVBP

AVBP FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

AVBP Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.67
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
3.14
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.67
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
3.14
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is AVBP's latest earnings report released?

    The most recent financial report for Arrivent biopharma, inc. common stock (AVBP) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating AVBP's short-term business performance and financial health. For the latest updates on AVBP's earnings releases, visit this page regularly.

  • How much cash does AVBP have?

    At the end of the period, Arrivent biopharma, inc. common stock (AVBP) held Total Cash and Cash Equivalents of 112.67M, accounting for 0.35 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is AVBP's EPS continuing to grow?

    According to the past four quarterly reports, Arrivent biopharma, inc. common stock (AVBP)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.83. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of AVBP?

    Arrivent biopharma, inc. common stock (AVBP)'s Free Cash Flow (FCF) for the period is -35.8M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 119.01% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.